Patient Types/Special Population

  • Pediatrics

    Treatment & Long-Acting Options For Youth

    Aditya Gaur, MD
    Member, Department of Infectious Diseases
    Director, Division of HIV Medicine
    St. Jude Children's Research Hospital
    Principal Investigator, IMPAACT 2017 (MOCHA Study)

    Ana Puga, MD
    Global Medical Lead, Pediatrics
    ViiV Healthcare

    Amy Min, PharmD, BCACP, AAHIVP
    Medical Science Liaison
    ViiV Healthcare

    Sonia Patel, PharmD
    Medical Science Liaison
    ViiV Healthcare

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director
    Dolutegravir Based Regimens
  • Women

    Including Women in Clinical Trials

    Dr. Kimberly Smith, VP Global Medical Strategy, Head of R&D
  • Treatment Naïve

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    Dolutegravir Based Regimens

    The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research
    Dolutegravir Based Regimens

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens
  • Suppressed Switch

    The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

    Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
    Cabotegravir

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator
    Dolutegravir Based Regimens

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research
    Dolutegravir Based Regimens

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Dolutegravir Based Regimens
  • Heavily Treatment Experienced

    Fostemsavir Clinical Pharmacology Overview

    Golkoo Morcos, PharmD, Medical Science Liaison
    Fostemsavir

    Fostemsavir Mechanism of Action

    Golkoo Morcos, PharmD, Medical Science Liaison
    Fostemsavir

    Viral Susceptibility of Rukobia

    Golkoo Morcos, PharmD, US Medical Director
    Fostemsavir